rmdopen.bmj21d
Pretreatment mortality risk prediction model in patients with polymyositis/dermatomyositis-associated interstitial lung disease
Objectives Risk prediction for patients with polymyositis/dermatomyositis-associated interstitial lung disease (PM/DM-ILD) is challenging due to heterogeneity in the ...
Cartesian Therapeutics Gets FDA Rare Pediatric Disease Designation for Dermatomyositis Treatment
Cartesian Therapeutics said it has received rare pediatric disease designation from the U.S. Food and Drug Administration for its Descartes-08 treatment of juvenile dermatomyositis.
Yahoo Finance13d
Cartesian Therapeutics Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile Dermatomyositis
has granted Rare Pediatric Disease Designation to Descartes-08 for the treatment of juvenile dermatomyositis (JDM). Descartes-08, Cartesian’s lead mRNA cell therapy candidate, is an autologous ...
Cartesian Therapeutics Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile Dermatomyositis
Descartes-08, Cartesian’s lead mRNA cell therapy candidate, is an autologous mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T) product candidate targeting B-cell maturation antigen ...
Investing9d
Cartesian shares hold as analyst reiterates price target on FDA nod
The Descartes-08 treatment is an mRNA-engineered, BCMA-targeted CAR-T therapy. While H.C. Wainwright's primary focus for Cartesian's valuation has been on the potential of Descartes-08 to treat ...
Targeted Oncology13d
NCCN Guidelines Add Denileukin Diftitox for CTCL Treatment
Denileukin diftitox, an IL-2-receptor-directed cytotoxin, has been added to the NCCN guidelines for the treatment of adult ...
MedPage Today2d
Kids With MS May Have Better Outcomes When Started on High-Efficacy Treatment Early
Among 282 patients with pediatric-onset MS, 39% started high-efficacy therapy early (at ages 12-17), and 61% started late ...